Claritev Corp (CTEV)


Claritev Corp is a healthcare technology company listed on the NYSE under the ticker CTEV. Through its subsidiaries, the company provides data analytics and technology-enabled solutions focused on end-to-end cost management, payment integrity, and revenue integrity for the U.S. healthcare industry. Its offerings include claims intelligence tools such as reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions that cover primary and complementary networks as well as network build and management services; and payment and revenue integrity services spanning clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity. Claritev also provides data and analytics products including PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company serves a broad customer base that includes commercial healthcare payers, third-party administrators, employers, brokers and consultants, providers, government healthcare payers, and system integrators. Founded in 1980 and headquartered in McLean, Virginia, it was formerly known as MultiPlan Corporation before changing its name in February 2025.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-CTEV
$25.74
-10.5% Downside
Fair
$37.67
30.9% Upside
Undervalued
Fair
0.0%
August 7, 2026
-1.7x
-2.0x
0.5x
513.5 M
5.216 B
90.1%
33.8%
-3.4
12.5%
Valuation • Fair Value

Claritev Corp (NYSE-CTEV) Fair Value by Valuation Model

Compare the primary fair value estimate for Claritev Corp (NYSE-CTEV) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$25.74

Estimated downside of 10.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$12.89

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$27.88

Comparable-company valuation reference.

Analyst Price Target

$37.67

Analysts imply upside of 30.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Claritev Corp (NYSE-CTEV) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Claritev Corp (NYSE-CTEV)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

978.8 M

Current operating scale indicator.

Revenue Forecast

992.8 M

Forward revenue estimate.

EBITDA

533.3 M

Current operating profitability reference.

EBITDA Forecast

607.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Claritev Corp (NYSE-CTEV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Claritev Corp (NYSE-CTEV)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.62

No elevated caution signal from this screen.

Altman Z-Score

-3.4

Lower score that deserves closer risk review.

FCF / Net Income

12.5%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Claritev Corp (NYSE-CTEV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Claritev Corp (NYSE-CTEV)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 7, 2026

Days to Earnings

17

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Claritev Corp (NYSE-CTEV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Claritev Corp (NYSE-CTEV) Stock Forecast & Technical Outlook

Review Claritev Corp (NYSE-CTEV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Claritev Corp (NYSE-CTEV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Claritev Corp (NYSE-CTEV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Claritev Corp (NYSE-CTEV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Claritev Corp (NYSE-CTEV) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Claritev Corp (NYSE-CTEV) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Claritev Corp (NYSE-CTEV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Claritev Corp (NYSE-CTEV) has a Strong Buy consensus, with 3 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 1
Sell 0
FAQ Fast Investor Answers

Claritev Corp (NYSE-CTEV) Stock FAQ

Quick answers about Claritev Corp (NYSE-CTEV) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$25.74
Estimated downside 10.5%
Valuation Rating
Overvalued
Estimated downside of 10.5%
Analyst Target
$37.67
Implied upside 30.9%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Claritev Corp (NYSE-CTEV) is $25.74. This implies an estimated downside of 10.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 10.5% versus the current market price.

The available analyst price target for Claritev Corp (NYSE-CTEV) is $37.67. The analyst target implies estimated upside of 30.9%.

The current financial health read for Claritev Corp (NYSE-CTEV) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Claritev Corp (NYSE-CTEV) is August 7, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Claritev Corp (NYSE-CTEV) is -1.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Claritev Corp is 513.5 M.

The current enterprise value listed for Claritev Corp is 5.216 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Claritev Corp is NYSE-CTEV, and the stock is listed on NYSE.

Claritev Corp (NYSE-CTEV) is listed on NYSE.

The current debt-to-total-capital ratio listed for Claritev Corp is 90.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Claritev Corp is 33.8%. Free float helps investors understand how much of the share base is available for public trading.